Company / EPS (Diluted)
Incyte EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.65
FY2025
5-year range
-$1.36 / $4.27
FY2021-FY2025
Trend
+74.3%
vs FY2024
Sector context
#18 of 204
Health Care
What the data says
Among 204 Health Care companies, Incyte is in the top 9% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.53 in FY2019 to $4.27 in FY2023.
Based on SEC 10-K filings.
2.65 in FY2025 with a 5-year CAGR of +39.0%. Top quartile in the Health Care sector.
Declined from $4.27 to $2.65 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +39.0%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 204This company $2.65 Sector average -$0.89
▼
+399.0% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 74.3% year-over-year.
- Ranks #18 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.65 | +74.3% |
| FY2024 | $1.52 | -64.4% |
| FY2023 | $4.27 | +414.0% |
| FY2022 | -$1.36 | -166.3% |
| FY2021 | $2.05 | +302.0% |
| FY2020 | $0.51 | +133.3% |
| FY2019 | -$1.53 | -383.3% |
| FY2018 | $0.54 | +1700.0% |
| FY2017 | $0.03 | +110.3% |
| FY2016 | -$0.29 | +48.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026